

Repurposing Tilmanocept for Cardiac Sarcoidosis

NCT07159074

Status	RECRUITING
Phase	Phase 2
Sponsor	Duke University
Enrollment	15 participants

Key Eligibility Criteria

Inclusion (13)

- Cohort 1:
- The participant has provided written informed consent with HIPAA (Health Information Portability and Accountability Act) or equivalent authorization before the initiation of any study-related procedures.
- Women of reproductive potential must have a negative urine pregnancy test at the time of the study.
- The participant is at least 18 years of age.
- The participant has a histological diagnosis sarcoidosis and meets 2014 HRS, 2014 WASOG, or 2016 JCS criteria for cardiac sarcoidosis.

... and 8 more (see full listing online)

Exclusion (8)

- The participant is pregnant or lactating.
- The participant size or weight is not compatible with imaging per the investigator.
- The participant has renal insufficiency as demonstrated by a glomerular filtration rate of < 30 mL/min.
- The participant has hepatic insufficiency as demonstrated by ALT (alanine aminotransferase [SGPT]) or AST (aspartate aminotransferase [SGOT]) greater than 3 times the upper limit of normal.
- The participant has any severe, acute, or chronic medical conditions and/or psychiatric conditions and/or laboratory abnormalities that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration that would deem the subject inappropriate for study participation.

... and 3 more (see full listing online)

Locations (1 total)

Duke University Hospital, Durham, North Carolina, United States